Geron Corporation

NasdaqGS:GERN Stock Report

Market Cap: US$757.9m

Geron Future Growth

Future criteria checks 5/6

Geron is forecast to grow earnings and revenue by 68.6% and 35.9% per annum respectively while EPS is expected to grow by 66.1% per annum.

Key information

68.6%

Earnings growth rate

66.14%

EPS growth rate

Biotechs earnings growth23.9%
Revenue growth rate35.9%
Future return on equityn/a
Analyst coverage

Good

Last updated08 May 2025

Recent future growth updates

Analysts Have Lowered Expectations For Geron Corporation (NASDAQ:GERN) After Its Latest Results

May 10
Analysts Have Lowered Expectations For Geron Corporation (NASDAQ:GERN) After Its Latest Results

Recent updates

Analysts Have Lowered Expectations For Geron Corporation (NASDAQ:GERN) After Its Latest Results

May 10
Analysts Have Lowered Expectations For Geron Corporation (NASDAQ:GERN) After Its Latest Results

Geron: Rytelo's Limited Adoption And Flat Demand Signal Troubled Outlook (Rating Downgrade)

May 09
author-image

EU Approval And US Initiatives Will Expand Future Markets

Apr 23 European expansion with RYTELO's approval and launch could significantly boost revenue through international growth and increased market reach.

Is Geron (NASDAQ:GERN) A Risky Investment?

Apr 17
Is Geron (NASDAQ:GERN) A Risky Investment?

Geron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish Comments

Mar 31

Geron Corp: How Concerned Should We Be About Rytelo Sales?

Mar 17

Risks Still Elevated At These Prices As Geron Corporation (NASDAQ:GERN) Shares Dive 45%

Mar 12
Risks Still Elevated At These Prices As Geron Corporation (NASDAQ:GERN) Shares Dive 45%

We're Hopeful That Geron (NASDAQ:GERN) Will Use Its Cash Wisely

Feb 27
We're Hopeful That Geron (NASDAQ:GERN) Will Use Its Cash Wisely

Geron: Rytelo's Market Share Concerns Justified As 3L Dominates Early Sales

Feb 26

Geron Corporation: Lackluster Share Price Performance Despite Reasonable Drug Launch

Feb 03

Geron: A Post Earnings And Funding Announcement Assessment

Nov 07

Is Geron (NASDAQ:GERN) Using Too Much Debt?

Oct 28
Is Geron (NASDAQ:GERN) Using Too Much Debt?

Geron's Rytelo Gains Traction Despite Competitive Pressures (Rating Upgrade)

Aug 12

Geron: Probabilistic And Modest Estimate Of Pricing For A Likely Acquisition

Jul 31

Does Geron (NASDAQ:GERN) Have A Healthy Balance Sheet?

Jul 12
Does Geron (NASDAQ:GERN) Have A Healthy Balance Sheet?

Geron: Innovative Rytelo Enters A Challenging MDS Market

Jun 08

Why We Think Geron Corporation's (NASDAQ:GERN) CEO Compensation Is Not Excessive At All

May 03
Why We Think Geron Corporation's (NASDAQ:GERN) CEO Compensation Is Not Excessive At All

Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy

Mar 15

Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA

Mar 05

Is Geron (NASDAQ:GERN) A Risky Investment?

Aug 25
Is Geron (NASDAQ:GERN) A Risky Investment?

Earnings and Revenue Growth Forecasts

NasdaqGS:GERN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202745795104N/A6
12/31/2026314-225N/A8
12/31/2025199-81-79N/A8
3/31/2025116-139-204-204N/A
12/31/202477-175-219-219N/A
9/30/202429-201-216-216N/A
6/30/20241-220-209-208N/A
3/31/20241-201-185-184N/A
12/31/20230-184-169-168N/A
9/30/20230-175-163-162N/A
6/30/20230-171-142-141N/A
3/31/20230-150-141-140N/A
12/31/20221-142-128-127N/A
9/30/20222-131-115-114N/A
6/30/20221-117-108-108N/A
3/31/20221-118-97-97N/A
12/31/20211-116-96-96N/A
9/30/20210-108-86-86N/A
6/30/20210-101-79-79N/A
3/31/20210-87-73-73N/A
12/31/20200-76-67-67N/A
9/30/20200-81-65-64N/A
6/30/20200-76-62-61N/A
3/31/20200-75-58-57N/A
12/31/20190-69-44-44N/A
9/30/20191-47-37-36N/A
6/30/20191-37-31-31N/A
3/31/20191-30-26-26N/A
12/31/20181-27N/A-21N/A
9/30/20181-27N/A-22N/A
6/30/20181-28N/A-21N/A
3/31/20181-28N/A-21N/A
12/31/20171-28N/A-21N/A
9/30/20171-29N/A-17N/A
6/30/20176-26N/A-19N/A
3/31/20176-28N/A-20N/A
12/31/20166-30N/A-18N/A
9/30/20166-30N/A-23N/A
6/30/2016371N/A-21N/A
3/31/2016371N/A-22N/A
12/31/2015360N/A-24N/A
9/30/2015360N/A10N/A
6/30/20151-37N/A10N/A
3/31/20151-37N/A11N/A
12/31/20141-36N/A9N/A
9/30/20141-36N/A-26N/A
6/30/20141-35N/A-27N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GERN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.8%).

Earnings vs Market: GERN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: GERN is expected to become profitable in the next 3 years.

Revenue vs Market: GERN's revenue (35.9% per year) is forecast to grow faster than the US market (8.6% per year).

High Growth Revenue: GERN's revenue (35.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if GERN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/15 04:50
End of Day Share Price 2025/05/15 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Geron Corporation is covered by 27 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Carter GouldBarclays
Peter LawsonBarclays
George ZavoicoB. Riley Securities, Inc.